TABLE 2

Adverse events and outcomes

MedDRA codePatientsSeverity (mild/moderate/severe/life-threatening)Seriousness (nonserious/serious)First 3 months after infusionOutcome at 12 months
Bronchitis100064518 (61.5)8/0/0/08/05Resolved
IPF clinical progression or worsening without hospitalisation100677615 (38.5)0/3/2/05/014 IPF progression
1 lung transplant
IPF worsening with hospitalisation (2 patients)10067761
10054112
3 (23.1)#0/2/1/00/311 death
Fever and/or dyspnoea after infusion10013968
10037660
3 (23.1)1/2/0/03/03Resolved
Upper respiratory tract infection/sinusitis100463092 (15.4)2/0/0/02/02Resolved
Flu-like syndrome100220042 (15.4)2/0/0/02/06Resolved
Acute gastroenteritis100667621 (7.7)1/0/0/01/01Resolved
Skin lesion100408821 (7.7)1/0/0/01/01Resolved
Legionella pneumonia with hospitalisation100357181 (7.7)0/0/0/10/101 death
Abdominal pain, weight decreased, and general deterioration10000081
10000159
10049438
1 (7.7)0/1/0/01/011 death
Prostate adenocarcinoma100608621 (7.7)0/1/0/00/10On treatment
Small cell lung cancer100410671 (7.7)1/0/0/00/10On treatment
Radiotherapy side-effects with hospitalisation (prostate cancer treatment)100377591 (7.7)0/1/0/01/00Resolved

Data are presented as n (%) or n. MedDRA: Medical Dictionary for Regulatory Activities; IPF: idiopathic pulmonary fibrosis. #: one patient was hospitalised twice during a 2-month period.